Researchers collect blood from Low-Platelet patients to uncover clues
NCT ID NCT06824727
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study collected one blood sample from 40 adults with very low platelets (30,000 or fewer per microliter) due to blood cancers or their treatments. The goal was simply to gather samples for research, not to test any new drug or therapy. Participants had to be 18 or older and could not have had recent chemotherapy or blood thinners.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could help researchers learn more about low platelet counts in blood cancer patients, potentially guiding future studies.
- What could go wrong
- This is a small, completed sample collection study with no treatment tested. It does not directly benefit participants and may not lead to any new therapies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
40 people
The number who actually took part.
- Started
-
Jan 2025
- Finished
-
Aug 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Samples will be collected from participants from the bone marrow transplant inpatient service and outpatient clinics.
- Ages
-
18 to 88 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Adults 18 years or older 2. Platelet counts of 30,000/mcl or less Exclusion Criteria: 1. Chemotherapy within the last 24 hours from the planned blood sample draw for research purposes. 2. Use of anticoagulant agents in the last 48 hours. 3. Active infection (i.e. one that has received less than 48 hours of active treatment). 4. Adults 89 years or older
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Hematologic malignancy are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Case Comprehensive Cancer Center, Cleveland Clinic Foundation Taussig Cancer Institute
Cleveland, Ohio, 44195, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can regional data improve bone marrow transplant results for blood cancers?
- Could a frailty score predict which older cancer patients survive intensive care?
- Why COVID-19 hits blood cancer patients harder: scientists map the immune clues
- Softer chemo before stem cell transplant aims to cure blood cancers in frail children
- Can a new drug stop the Body's attack after stem cell transplants?
- A diet tweak may boost platelets in a bleeding disorder